Prothrombotic gene mutations in patients with sudden sensorineural hearing loss and cardiovascular thrombotic disease

Pasquale Capaccio1, Valeria Cuccarini, Francesco Ottaviani

  • 1Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, Milan, Italy.

Insights

Sudden hearing loss may stem from vascular issues. Patients with cardiovascular events and hearing loss showed higher risks for prothrombotic gene mutations, suggesting a multifactorial cause.

Area of Science:

  • Vascular Medicine
  • Genetics
  • Otolaryngology

Background:

  • Sudden sensorineural hearing loss (SSNHL) is often linked to impaired cochlear blood flow.
  • Prothrombotic gene mutations are associated with vascular disorders and can contribute to SSNHL.
  • This study investigated prothrombotic risk factors in SSNHL patients with prior cardiovascular events.

Purpose of the Study:

  • To assess the prevalence of prothrombotic risk factors in patients experiencing sudden sensorineural hearing loss.
  • To explore the potential vascular pathogenesis of SSNHL, particularly in individuals with a history of cardiovascular disease.
  • To support the hypothesis that microvascular impairment contributes to SSNHL.

Main Methods:

  • Hematologic tests were performed on 10 SSNHL patients with cardiovascular history, including genotyping for MTHFR C677T/A1298C, prothrombin G20210A, platelet GlyIIIaA1/A2, and V Leiden G1691A.
  • Tests also measured fibrinogen, cholesterol, homocysteine, and folate levels.
  • Results were compared to 100 SSNHL patients without cardiovascular history and 200 healthy controls.

Main Results:

  • Two patients had two mutant alleles, six had three, and two had four.
  • Mean homocysteine, cholesterol, and fibrinogen levels exceeded normal limits.
  • Multiple prothrombotic mutations were significantly more frequent in the SSNHL patient group compared to controls.

Conclusions:

  • A multifactorial mechanism involving inherited and acquired prothrombotic factors likely underlies cochlear microvascular impairment in SSNHL.
  • Hematologic investigation, including specific gene genotyping, can identify patients at risk for recurrent hearing loss and other microvascular diseases.
  • This testing may be beneficial for cases of idiopathic SSNHL.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...